Laboratories, Inc., USA
As filed · General Updates
M&AWatchMajormateriality 79 out of 100
What happened
FactLaboratories, Inc., USA. The cumulative market size for the acquired portfolio is ~USD 57 million as per IQVIA data of 2025. Total consideration for acquisition of the said ANDAs is USD 2.075 million (~INR 176 million).
Why it matters
CapitSignal interpretationAn acquisition spends cash or issues shares today for earnings that arrive later, so the price paid and the funding route decide whether holders gain.
Scale
- 0.8% of FY26 revenue
₹17.6 Cr stated in the filing against ₹2,180.14 Cr revenue (FY26, standalone)
Source: financial_facts · exchange_table
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Margins
RevisedEarlierQ1 FY27
EBITDA to PAT conversion at ~50%+
NowQ1 FY27
We expect gross margins to remain in the 58-60% range.
Change
FactTarget revision
Implication
CapitSignal interpretationThe stated figure moved 20.00%.confidence 60%
Watch next
Fact- Consideration and how it is funded
- Revenue and profit of the target
- Expected completion date
- Aspire to focus on North America Business Revenue of ~$375m by FY28 despite current external headwinds (management committed by FY28)
- Continue to add new customers in Europe by leveraging strong commercial presence and robust supply chain (management committed by FY27)
Evidence
- Strides acquires identified ANDAs from Nostrum Laboratories, Inc., USA(opens the original filing in a new tab)
- Earlier statement · Q1 FY27
- Latest statement · Q1 FY27
- Earlier statement · Q1 FY27
How CapitSignal classified this
- Reasoning:
- ACQUISITION base 74; +5 quantified amount; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 75%